Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Domestically listed pharmaceutical companies' API revenue ranking released, Healthy Yuan's strength leaps to a high position
Published Time：
2021-04-13
In recent years, the concept of "Made in China" has been gaining popularity, and active pharmaceutical ingredients (APIs), known as the "chips" of the pharmaceutical industry, are gradually becoming a new label for Chinese manufacturing in the biopharmaceutical sector. After the stress test of the COVID-19 pandemic, the crucial industrial position of domestic APIs has become even more prominent. Recently, the top 15 domestic listed pharmaceutical companies in terms of API revenue in 2020 were announced! Joincare Pharmaceutical Group Industry Co., Ltd. ranked sixth with API intermediate revenue of 3.935 billion yuan.
Data Source: Listed Company Announcements, Compiled by Pharmaceutics Vertical
From the development experience of pharmaceutical companies in Europe and the United States, the pharmaceutical manufacturing industry actually has high technological barriers and entry thresholds. The key to competing lies in the iteration of product layouts, the accumulation of quality systems, and the application of innovative achievements, etc. As the "chips" of the pharmaceutical industry, integrated API and formulation is an inevitable trend for traditional chemical drugs. In recent years, the importance of APIs has also increased significantly in various countries.
With the optimized development of the competitive landscape in the pharmaceutical industry, the API industry will benefit in the long term from the global transfer of the pharmaceutical industry chain and the continuous increase in market demand. However, leading domestic integrated API and formulation companies are still in their early stages of development, and there is still enormous potential for future growth.
In 2020, after the impact of the epidemic, the characteristics of coexistence of challenges and opportunities were particularly prominent in the pharmaceutical industry. Relying on the innovative R&D technology accumulated over the years in the pharmaceutical field, HealthGen precisely grasped market opportunities and expanded overseas markets, enabling the release of its production capacity layout in the chemical drug field and achieving rapid growth in sales of APIs and intermediates such as meropenem (powder for injection), with API intermediate revenue increasing by 12.24% year-on-year.
Currently, there are huge structural substitution opportunities in the domestic API and formulation markets. Under the market environment where consistency evaluation and volume-based procurement are continuously promoted, as long as domestic pharmaceutical manufacturing enterprises can achieve the mass production of new varieties and effectively seize market share, the market potential will be considerable.
HealthGen, which has been among the top 15 listed pharmaceutical companies nationwide, has developed over many years, focusing on the areas of antimicrobials, anti-tumor drugs, sex hormones, digestion, nerves, and respiration, forming a relatively clear product R&D pipeline, and major products are gradually entering the harvest period.
In the future, with the continuous expansion of rapidly increasing drugs and the promotion of integrated formulation and other strategies, HealthGen will stand out in the high-end specialty market.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.